RUNX3 Suppresses Gastric Epithelial Cell Growth by Inducing p21^WAF1/Cip1 Expression in Cooperation with Transforming Growth Factor β-Activated SMAD

REFERENCES

• Balmain, A. 2002. Cancer new-age tumour suppressors. Nature 417:235–237.
   PubMed Web of Science ®Google Scholar
• Chellappan, S. P., S. Hiebert, M. Mudryj, J. M. Horowitz, and J. R. Nevins. 1991. The E2F transcription factor is a cellular target for the RB protein. Cell 65:1053–1061.
   PubMed Web of Science ®Google Scholar
• Datta, P. K., M. C. Blake, and H. L. Moses. 2000. Regulation of plasminogen activator inhibitor-1 expression by transforming growth factor-beta-induced physical and functional interactions between smads and Sp1. J. Biol. Chem. 275:40014–40019.
   PubMed Web of Science ®Google Scholar
• Derynck, R., R. J. Akhurst, and A. Balmain. 2001. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29:117–129.
   PubMed Web of Science ®Google Scholar
• el Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825.
   PubMed Web of Science ®Google Scholar
• Goel, A., C. N. Arnold, P. Tassone, D. K. Chang, D. Niedzwiecki, J. M. Dowell, L. Wasserman, C. Compton, R. J. Mayer, M. M. Bertagnolli, and C. R. Boland. 2004. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int. J. Cancer 112:754–759.
   PubMed Web of Science ®Google Scholar
• Guo, W. H., L. Q. Weng, K. Ito, L. F. Chen, H. Nakanishi, M. Tatematsu, and Y. Ito. 2002. Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor. Oncogene 21:8351–8355.
   PubMedGoogle Scholar
• Hanai, J., L. F. Chen, T. Kanno, N. Ohtani-Fujita, W. Y. Kim, W. H. Guo, T. Imamura, Y. Ishidou, M. Fukuchi, M. J. Shi, J. Stavnezer, M. Kawabata, K. Miyazono, and Y. Ito. 1999. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Cα promoter. J. Biol. Chem. 274:31577–31582.
   PubMed Web of Science ®Google Scholar
• Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–816.
   PubMed Web of Science ®Google Scholar
• Inoue, K., S. Ozaki, T. Shiga, K. Ito, T. Masuda, N. Okado, T. Iseda, S. Kawaguchi, M. Ogawa, S. C. Bae, N. Yamashita, S. Itohara, N. Kudo, and Y. Ito. 2002. Runx3 controls the axonal projection of proprioceptive dorsal root ganglion neurons. Nat. Neurosci. 5:946–954.
   PubMed Web of Science ®Google Scholar
• Johnson, D. G., J. K. Schwarz, W. D. Cress, and J. R. Nevins. 1993. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365:349–352.
   PubMed Web of Science ®Google Scholar
• Kang, G. H., S. Lee, H. J. Lee, and K. S. Hwang. 2004. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J. Pathol. 202:233–240.
   PubMed Web of Science ®Google Scholar
• Kim, T. Y., H. J. Lee, K. S. Hwang, M. Lee, J. W. Kim, Y. J. Bang, and G. H. Kang. 2004. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab. Investig. 84:479–484.
   PubMed Web of Science ®Google Scholar
• Ku, J. L., S. B. Kang, Y. K. Shin, H. C. Kang, S. H. Hong, I. J. Kim, J. H. Shin, I. O. Han, and J. G. Park. 2004. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 23:6736–6742.
   PubMedGoogle Scholar
• Lee, B., K. Thirunavukkarasu, L. Zhou, L. Pastore, A. Baldini, J. Hecht, V. Geoffroy, P. Ducy, and G. Karsenty. 1997. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat. Genet. 16:307–310.
   PubMed Web of Science ®Google Scholar
• Lee, M., J. Kwon, S. N. Kim, J. E. Kim, W. S. Koh, E. J. Kim, M. K. Chung, S. S. Han, and C. W. Song. 2003. cDNA microarray gene expression profiling of hydroxyurea, paclitaxel, and p-anisidine, genotoxic compounds with differing tumorigenicity results. Environ. Mol. Mutagen. 42:91–97.
   PubMed Web of Science ®Google Scholar
• Levanon, D., D. Bettoun, C. Harris-Cerruti, E. Woolf, V. Negreanu, R. Eilam, Y. Bernstein, D. Goldenberg, C. Xiao, M. Fliegauf, E. Kremer, F. Otto, O. Brenner, A. Lev-Tov, and Y. Groner. 2002. The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. EMBO J. 21:3454–3463.
   PubMed Web of Science ®Google Scholar
• Li, Q. L., K. Ito, C. Sakakura, H. Fukamachi, K. Inoue, X. Z. Chi, K. Y. Lee, S. Nomura, C. W. Lee, S. B. Han, H. M. Kim, W. J. Kim, H. Yamamoto, N. Yamashita, T. Yano, T. Ikeda, S. Itohara, J. Inazawa, T. Abe, A. Hagiwara, H. Yamagishi, A. Ooe, A. Kaneda, T. Sugimura, T. Ushijima, S. C. Bae, and Y. Ito. 2002. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109:113–124.
   PubMed Web of Science ®Google Scholar
• Li, Q. L., H. R. Kim, W. J. Kim, J. K. Choi, Y. H. Lee, H. M. Kim, L. S. Li, H. Kim, J. Chang, Y. Ito, L. K. Youl, and S. C. Bae. 2004. Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem. Biophys. Res. Commun. 314:223–228.
   PubMedGoogle Scholar
• Look, A. T. 1997. Oncogenic transcription factors in the human acute leukemias. Science 278:1059–1064.
   PubMed Web of Science ®Google Scholar
• Lutterbach, B., J. J. Westendorf, B. Linggi, S. Isaac, E. Seto, and S. W. Hiebert. 2000. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J. Biol. Chem. 275:651–656.
   PubMed Web of Science ®Google Scholar
• Malliri, A., W. A. Yeudall, M. Nikolic, D. H. Crouch, E. K. Parkinson, and B. Ozanne. 1996. Sensitivity to transforming growth factor beta 1-induced growth arrest is common in human squamous cell carcinoma cell lines: c-MYC down-regulation and p21waf1 induction are important early events. Cell Growth Differ. 7:1291–1304.
   PubMedGoogle Scholar
• Massague, J., S. W. Blain, and R. S. Lo. 2000. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103:295–309.
   PubMed Web of Science ®Google Scholar
• Mizushima, S., and S. Nagata. 1990. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res. 18:5322.
   PubMed Web of Science ®Google Scholar
• Moustakas, A., and D. Kardassis. 1998. Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc. Natl. Acad. Sci. USA 95:6733–6738.
   PubMed Web of Science ®Google Scholar
• Mundlos, S., F. Otto, C. Mundlos, J. B. Mulliken, A. S. Aylsworth, S. Albright, D. Lindhout, W. G. Cole, W. Henn, J. H. Knoll, M. J. Owen, R. Mertelsmann, B. U. Zabel, and B. R. Olsen. 1997. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 89:773–779.
   PubMed Web of Science ®Google Scholar
• Okuda, T., J. van Deursen, S. W. Hiebert, G. Grosveld, and J. R. Downing. 1996. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321–330.
   PubMed Web of Science ®Google Scholar
• Oshimo, Y., N. Oue, Y. Mitani, H. Nakayama, Y. Kitadai, K. Yoshida, Y. Ito, K. Chayama, and W. Yasui. 2004. Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma. Pathobiology 71:137–143.
   PubMedGoogle Scholar
• Otto, F., A. P. Thornell, T. Crompton, A. Denzel, K. C. Gilmour, I. R. Rosewell, G. W. Stamp, R. S. Beddington, S. Mundlos, B. R. Olsen, P. B. Selby, and M. J. Owen. 1997. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89:765–771.
   PubMed Web of Science ®Google Scholar
• Pardali, K., A. Kurisaki, A. Moren, P. ten Dijke, D. Kardassis, and A. Moustakas. 2000. Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. J. Biol. Chem. 275:29244–29256.
   PubMed Web of Science ®Google Scholar
• Park, K., S. J. Kim, Y. J. Bang, J. G. Park, N. K. Kim, A. B. Roberts, and M. B. Sporn. 1994. Genetic changes in the transforming growth factor beta (TGF-β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β. Proc. Natl. Acad. Sci. USA 91:8772–8776.
   PubMed Web of Science ®Google Scholar
• Polyak, K., M. H. Lee, H. Erdjument-Bromage, A. Koff, J. M. Roberts, P. Tempst, and J. Massague. 1994. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59–66.
   PubMed Web of Science ®Google Scholar
• Seoane, J., H. V. Le, L. Shen, S. A. Anderson, and J. Massague. 2004. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117:211–223.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J., and J. M. Roberts. 1995. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1149–1163.
   PubMed Web of Science ®Google Scholar
• Somasundaram, K., H. Zhang, Y. X. Zeng, Y. Houvras, Y. Peng, H. Zhang, G. S. Wu, J. D. Licht, B. L. Weber, and W. S. El Deiry. 1997. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature 389:187–190.
   PubMed Web of Science ®Google Scholar
• Taniuchi, I., M. Osato, T. Egawa, M. J. Sunshine, S. C. Bae, T. Komori, Y. Ito, and D. R. Littman. 2002. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 111:621–633.
   PubMed Web of Science ®Google Scholar
• van Wijnen, A. J., G. S. Stein, J. P. Gergen, Y. Groner, S. W. Hiebert, Y. Ito, P. Liu, J. C. Neil, M. Ohki, and N. Speck. 2004. Nomenclature for Runt-related (RUNX) proteins. Oncogene 23:4209–4210.
   PubMedGoogle Scholar
• Wada, M., S. Yazumi, S. Takaishi, K. Hasegawa, M. Sawada, H. Tanaka, H. Ida, C. Sakakura, K. Ito, Y. Ito, and T. Chiba. 2004. Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines. Oncogene 23:2401–2407.
   PubMed Web of Science ®Google Scholar
• Westendorf, J. J., S. K. Zaidi, J. E. Cascino, R. Kahler, A. J. van Wijnen, J. B. Lian, M. Yoshida, G. S. Stein, and X. Li. 2002. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol. Cell. Biol. 22:7982–7992.
   PubMed Web of Science ®Google Scholar
• Wheeler, J. C., C. VanderZwan, X. Xu, D. Swantek, W. D. Tracey, and J. P. Gergen. 2002. Distinct in vivo requirements for establishment versus maintenance of transcriptional repression. Nat. Genet. 32:206–210.
   PubMed Web of Science ®Google Scholar
• Woolf, E., C. Xiao, O. Fainaru, J. Lotem, D. Rosen, V. Negreanu, Y. Bernstein, D. Goldenberg, O. Brenner, G. Berke, D. Levanon, and Y. Groner. 2003. Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc. Natl. Acad. Sci. USA 100:7731–7736.
   PubMed Web of Science ®Google Scholar
• Xiao, W. H., and W. W. Liu. 2004. Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma. World J. Gastroenterol. 10:376–380.
   PubMed Web of Science ®Google Scholar
• Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366:701–704.
   PubMed Web of Science ®Google Scholar
• Yamada, K., M. Matsuki, Y. Morishima, E. Ueda, K. Tabata, H. Yasuno, M. Suzuki, and K. Yamanishi. 1997. Activation of the human transglutaminase 1 promoter in transgenic mice: terminal differentiation-specific expression of the TGM1-lacZ transgene in keratinized stratified squamous epithelia. Hum. Mol. Genet. 6:2223–2231.
   PubMedGoogle Scholar
• Yanagawa, N., G. Tamura, H. Oizumi, N. Takahashi, Y. Shimazaki, and T. Motoyama. 2003. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci. 94:589–592.
   PubMed Web of Science ®Google Scholar